157 related articles for article (PubMed ID: 37253281)
1. Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS).
Jones A; Peers K; Wierzbicki AS; Ramachandran R; Mansfield M; Dawson C; Ochoa-Ferraro A; Soran H; Jenkinson F; McDowell I; Downie P; Hamilton P; Jones RD
Atherosclerosis; 2023 Jun; 375():67-74. PubMed ID: 37253281
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Gouni-Berthold I; Alexander VJ; Yang Q; Hurh E; Steinhagen-Thiessen E; Moriarty PM; Hughes SG; Gaudet D; Hegele RA; O'Dea LSL; Stroes ESG; Tsimikas S; Witztum JL;
Lancet Diabetes Endocrinol; 2021 May; 9(5):264-275. PubMed ID: 33798466
[TBL] [Abstract][Full Text] [Related]
3. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.
Witztum JL; Gaudet D; Arca M; Jones A; Soran H; Gouni-Berthold I; Stroes ESG; Alexander VJ; Jones R; Watts L; Xia S; Tsimikas S
J Clin Lipidol; 2023; 17(3):342-355. PubMed ID: 37100699
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chylomicronemia.
Navarro Hermoso A; Valdivielso P
Clin Investig Arterioscler; 2021 May; 33 Suppl 2():75-79. PubMed ID: 34006359
[TBL] [Abstract][Full Text] [Related]
5. Volanesorsen for treatment of familial chylomicronemia syndrome.
Lazarte J; Hegele RA
Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):685-693. PubMed ID: 34261380
[TBL] [Abstract][Full Text] [Related]
6. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
Witztum JL; Gaudet D; Freedman SD; Alexander VJ; Digenio A; Williams KR; Yang Q; Hughes SG; Geary RS; Arca M; Stroes ESG; Bergeron J; Soran H; Civeira F; Hemphill L; Tsimikas S; Blom DJ; O'Dea L; Bruckert E
N Engl J Med; 2019 Aug; 381(6):531-542. PubMed ID: 31390500
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
[TBL] [Abstract][Full Text] [Related]
8. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
Esan O; Wierzbicki AS
Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844
[TBL] [Abstract][Full Text] [Related]
9. Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia.
Kolovou G; Kolovou V; Katsiki N
J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207255
[TBL] [Abstract][Full Text] [Related]
10. Volanesorsen for treatment of patients with familial chylomicronemia syndrome.
Warden BA; Duell PB
Drugs Today (Barc); 2018 Dec; 54(12):721-735. PubMed ID: 30596391
[TBL] [Abstract][Full Text] [Related]
11. Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of Volanesorsen.
den Hollander B; Brands MM; Nijhuis IJM; Doude van Troostwijk LJAE; van Essen P; Hofsteenge GH; Koot BG; Müller AR; Tseng LA; Stroes ESG; van de Ven PM; Wiegman A; van Karnebeek CDM
Mol Genet Metab; 2024 May; 142(1):108347. PubMed ID: 38401382
[TBL] [Abstract][Full Text] [Related]
12. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".
Moulin P; Dufour R; Averna M; Arca M; Cefalù AB; Noto D; D'Erasmo L; Di Costanzo A; Marçais C; Alvarez-Sala Walther LA; Banach M; Borén J; Cramb R; Gouni-Berthold I; Hughes E; Johnson C; Pintó X; Reiner Ž; van Lennep JR; Soran H; Stefanutti C; Stroes E; Bruckert E
Atherosclerosis; 2018 Aug; 275():265-272. PubMed ID: 29980054
[TBL] [Abstract][Full Text] [Related]
13. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study.
Arca M; Hsieh A; Soran H; Rosenblit P; O'Dea L; Stevenson M
Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):537-546. PubMed ID: 29889589
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of lomitapide in familial chylomicronaemia syndrome.
Cefalù AB; D'Erasmo L; Iannuzzo G; Noto D; Giammanco A; Montali A; Zambon A; Forte F; Suppressa P; Giannini S; Barbagallo CM; Ganci A; Nardi E; Vernuccio F; Caldarella R; Ciaccio M; Arca M; Averna M
Atherosclerosis; 2022 Oct; 359():13-19. PubMed ID: 36152419
[TBL] [Abstract][Full Text] [Related]
15. Volanesorsen: First Global Approval.
Paik J; Duggan S
Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome.
Cefalù AB; Giammanco A; Noto D; Spina R; Cabibi D; Barbagallo CM; Averna M
Endocrine; 2021 Feb; 71(2):344-350. PubMed ID: 33006726
[TBL] [Abstract][Full Text] [Related]
17. Monogenic hypertriglyceridemia and recurrent pancreatitis in a homozygous carrier of a rare APOA5 mutation: a case report.
Makhmudova U; Schulze PC; Lorkowski S; März W; Geiling JA; Weingärtner O
J Med Case Rep; 2024 Jun; 18(1):278. PubMed ID: 38872171
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
Chaudhry R; Viljoen A; Wierzbicki AS
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
[TBL] [Abstract][Full Text] [Related]
19. Two successful pregnancies -in patients taking Volanesorsen for familial chylomicronemia syndrome.
Wanninayake S; Ochoa-Ferraro A; Patel K; Ramachandran R; Wierzbicki AS; Dawson C
JIMD Rep; 2024 Jul; 65(4):249-254. PubMed ID: 38974616
[TBL] [Abstract][Full Text] [Related]
20. Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen: A case report.
Tünnemann-Tarr A; Scharnagl H; Katzmann JL; Stürzebecher P; Laufs U
Medicine (Baltimore); 2021 Oct; 100(42):e27573. PubMed ID: 34678899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
